Natural Psilocybin2024-05-15T11:29:12+02:00

Informed by nature
and guided by science

Informed
by nature
and guided
by science

Pioneering the use of natural psychedelics for mental health

We are a life science biotechnology company developing innovative, safe and effective psychedelic and nature-centred solutions for mental health.

Our key focus area is palliative care. In particular, Psyence is targeting the indications of anxiety and depression, and associated ailments, within the context of palliative care.

Our key focus area is palliative care. and associated ailments, within the context of palliative care. In particular, Psyence is targeting the indications of anxiety and depression,

We develop natural psilocybin products, medicinal formulations and treatment protocols to treat mental health disorders in a clinical environment. Psyence Therapeutics is now housed in the NASDAQ listed entity Psyence Biomedical Ltd (NASDAQ:PBM).

We operate one of the first federally licensed ISO22000 certified psilocybin cultivation and production facilities in the world.

Our range of functional mushroom wellness products harness the power of adaptogens – non-toxic, non-psychoactive fungi used in ancient medicine for their stress relieving and general wellness benefits.

Learn More

Bringing together leaders in the business of medicine and science
 Our Team Our scientific and medical team are experts in neurology and the development and commercialisation of pharmaceutical products. Our global executive team has extensive capital market and business building experience and a track record for creating shareholder value and achieving sustainable growth Psyence Production - Psilocybin

Bringing together leaders in the business of medicine and science

Our scientific and medical team are experts in neurology and the development and commercialisation of pharmaceutical products. Our global executive team has extensive capital market and business building experience and a track record for creating shareholder value and achieving sustainable growth.

Our News

Our Global Footprint

Psyence is listed on the Canadian Stock Exchange (CSE: PSYG) and quoted on the US OTCQB® Venture Market (OTCQB: PSYGF). Our diversified business has a global footprint with operations in multiple legal jurisdictions.

Our Global Footprint

Psyence is listed on the Canadian Stock Exchange (CSE: PSYG) and quoted on the US OTCQB® Venture Market (OTCQB: PSYGF). Our diversified business has a global footprint with operations in multiple legal jurisdictions.

Our News

Psyence Group Enters into Agreements with its NASDAQ-Listed Associate, Psyence Biomedical, to settle outstanding obligations

December 7, 2024|

Psyence Group hereby announces that it has entered into an addendum to the previously announced debt-for-equity swap agreements (the "Debt Swap Agreements") with its NASDAQ-listed associate, Psyence Biomedical Ltd (NASDAQ: PBM) ("PBM" or "Psyence Biomed"), pursuant to which Psyence Biomed has agreed to issue to the Company 337,750 Psyence Biomed common shares at a deemed price of US$3.88 per common share, in exchange for the discharging of the balance of Psyence Biomed's obligations due under the Debt Swap Agreements and a promissory note, dated January 25, 2024, issued by Psyence Biomed to the Company in connection with Psyence Biomed's listing of its common shares on the NASDAQ in January 2024.

Read More

Contact Info

General inquiries — info@psyence.com

Media inquiries — media@psyence.com

Investor inquiries — ir@psyence.com

Tel: +1-416-477-1708

Address: 121 Richmond Street West, Penthouse Suite, 1300, Toronto ON M5H2K1, Canada

Sign Up To Our Newsletter

Sign Up To Receive Our Communications

By submitting this form, you are consenting to receive marketing emails from: Psyence Group Inc, 121 Richmond Street West, Penthouse Suite, 1300, Toronto ON M5H2K1 Canada You can revoke your consent to receive emails at any time by using the SafeUnsubscribe® link, found at the bottom of every email.

Psyence Group Inc. (“Psyence”) is currently advancing a proposed reverse takeover transaction with GoldCoast Resource Corp., a private mineral exploration company focused on offshore gold exploration in Ghana. Upon completion of the transaction, the resulting issuer is expected to pursue the business of GoldCoast, subject to receipt of all required regulatory and shareholder approvals. There can be no assurance that the proposed transaction will be completed as contemplated or at all, or that any particular outcome will be achieved.

In connection with the proposed transaction, Psyence has paused its initiatives involving nature-derived psilocybin products. All information on this website relating to Psyence’s research and development initiatives involving nature-derived psilocybin products is historical in nature, is provided for information purposes only, and does not reflect Psyence’s current operations, strategic focus, or future plans.

By continuing to use this website, you acknowledge and agree that:

The website content relating to nature-derived psilocybin products is historical and may be incomplete, inaccurate, or outdated; and
Psyence has no obligation to update such historical information except as required by applicable law or regulation.

Please refer to Psyence’s most recent Management’s Discussion and Analysis, available under Psyence’s profile at www.sedarplus.ca, for the latest information on the company.

Go to Top